Home Newsfeeds Mizuho Maintains Buy on Dover, Lowers Price Target to $155

Mizuho Maintains Buy on Dover, Lowers Price Target to $155

Mizuho analyst Brett Linzey maintains Dover (NYSE:DOV) with a Buy and lowers the price target from $175 to $155.

byBenzinga Newsdesk

July 18, 2022

1 minute read

Mizuho analyst Brett Linzey maintains Dover (NYSE:DOV) with a Buy and lowers the price target from $175 to $155.

Analyst Ratings

Where Qualcomm Stands With Analysts

By Benzinga Insights

April 25, 3:01 PM

Qualcomm (NASDAQ:QCOM) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

QCOM

What’s Going On With SiNtx Technologies Stock?

By Erica Kollmann

April 17, 12:39 PM

Sintx Technologies will hold a special meeting of stockholders on May 14 to vote on the proposal of a potential reverse stock split of all issued and outstanding shares of common stock at a ratio of not less than 1-for-100 and not greater than 1-for-300.

SINT

Alibaba Partners With Saudi Arabia And UAE Firms As China Gets Closer To Gulf

By Benzinga Neuro

February 14, 6:12 AM

This development comes at a time when the Gulf nations are strengthening their ties with China, seeking investments to diversify their economies beyond oil.

BABA

‘Maker Of Promising Alzheimer’s Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage’ – CNBC

By Happy Mohamed

February 17, 10:52 AM

https://www.cnbc.com/2023/02/17/maker-of-promising-alzheimer-drug-leqembi-expects-fdas-full-approval-this-summer.html Eisai is anticipating full FDA approval of its early Alzheimer’s treatment, Leqembi, as soon

BIIB

Mizuho Maintains Buy on Dover, Lowers Price Target to $155

Related Posts

Where Qualcomm Stands With Analysts

What’s Going On With SiNtx Technologies Stock?

Alibaba Partners With Saudi Arabia And UAE Firms As China Gets Closer To Gulf

‘Maker Of Promising Alzheimer’s Drug Leqembi Expects Full FDA Approval This Summer, Expanded Medicare Coverage’ – CNBC